High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse.


Bakkaloglu S. A., Soylemezoglu O., Buyan N., Funahashi T., Elhan A., Peru H., ...Daha Fazla

Pediatric nephrology (Berlin, Germany), cilt.20, sa.4, ss.474-7, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 4
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1007/s00467-004-1770-z
  • Dergi Adı: Pediatric nephrology (Berlin, Germany)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.474-7
  • Anahtar Kelimeler: steroid-responsive nephrotic syndrome, adiponectin, children, hyperlipidemia, ADIPOSE-SPECIFIC PROTEIN, SOLUBLE LEPTIN RECEPTOR, PLASMA-PROTEIN, CHILDREN, OBESITY, CLONING, TISSUE, RISK
  • Gazi Üniversitesi Adresli: Evet

Özet

Adiponectin (ADPN), exclusively expressed and secreted from adipocytes, is a recently discovered protein hormone with anti-atherogenic and anti-inflammatory properties in contrast to other well-known adipocytokines. It has independent negative associations with obesity and hyperinsulinemia/insulin resistance. Apart from chronic renal failure, nephrotic syndrome was suggested as the only renal disease condition associated with raised plasma ADPN levels in adults. We aimed to evaluate the effect of nephrotic state on serum adiponectin ( ADPN) levels in pediatric patients with steroid-responsive nephrotic syndrome (SRNS) by comparing the levels in relapse and remission as well as in control subjects and documenting possible relationships between ADPN and proteinuria as well as serum protein/lipid parameters. 34 patients with SRNS and 22 healthy age, sex and BMI-matched control subjects were enrolled into the study. 15 of the 34 SRNS patients had active diseases, and these were known as the SRNS-relapse group ( ten relapsed and five newly-diagnosed patients), while the remaining 19 were in complete remission ( the SRNS-remission group). Serum ADPN levels, blood chemistry ( protein/albumin, triglyceride ( TG), cholesterol (Cho) and lipoprotein levels) and 24-hour proteinuria were studied. ADPN levels were determined by ELISA. As expectedly, there were significant alterations in serum protein-lipid parameters and 24-hour proteinuria levels in SRNS patients consistent with their disease activity. SRNS-relapse patients had substantially higher ADPN levels ( 36.77 +/- 15.06 ( 5.61 - 59.41, median 39.84) mug/ml), compared to those in SRNS-remission and control groups ( 14.17 +/- 6.02 ( 3.28 - 29.40, median 12.80) mug/ml and 11.84 +/- 7.53 ( 2.81 - 31.46, median 10.85) mug/ml, respectively, p= 0.001). There were strong positive correlations between serum ADPN levels and Cho ( r= 0.637, p= 0.000), TG ( r= 0.516, p= 0.002), low density lipoprotein ( r= 0.614, p= 0.000) levels and 24-hour proteinuria ( r= 0.828, p= 0.000) levels, whereas protein ( r= - 0.695, p= 0.000) and albumin ( r= 0.732, p= 0.000) levels were inversely correlated with ADPN levels. Regression analysis showed a significant correlation between ADPN and proteinuria ( p= 0.000). In conclusion, remarkably increased serum ADPN levels were detected in SRNS-relapse compared to those in SRNS-remission. This phenomenon might be the reflection of a compensatory response to nephrotic state characterized by massive proteinuria, hypoalbuminemia and hyperlipidemia.